News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Phase I/II Study of Dianhydrogalactitol (Val-083) in Patients with Recurrent Malignant Glioma

Al's Comment:

This small study was in patients with glioblastoma multiforme who failed Temodar and Avastin. In general, patients who failed these 2 treatments live an average of an additional 2 months without further treatment, or 5.2 months with salvage therapies.  With high dose Val-083, median survival was 9.2 more with 1/3 of the patients being alive at the 12 month point. Pretty good results in a very bad patient population.


Posted on: 11/21/2015

 Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma

Click HERE for the poster

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740